4-(Pyrrolidin-2-yl)piperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(Pyrrolidin-2-yl)piperidine
• 英文别名: 4-pyrrolidin-2-ylpiperidine
• 化学式: C₉H₁₈N₂
• 分子量: 154.25
• InChiKey: IUZGEJUVHUPYAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS
  申请人：Seth Punit P.

  公开号：US20100130513A1

  公开（公告）日：2010-05-27

  Provided are compounds of the formula: wherein R N1 is a substituent of formula G 1 -NX 1 X 2 , wherein G 1 is an optionally further substituted alkylene, which optionally forms, together with R N2 , a cyclic group, and each of X 1 and X 2 is independently H or an N-substituent, or X 1 and X 2 together form a heterocyclic ring, or X 1 together with G 1 forms a cyclic group and X 2 is H or an N-substituent; and each of Z 1 , Z 2 , Z 3 and Z 4 is H or a substituent, or two of Z 1 , Z 2 , Z 3 and Z 4 together form an optionally substituted ring, and further wherein at least one of Z 1 , Z 2 , Z 3 and Z 4 is other than H, and salts thereof, pharmaceutical compositions and methods of using the compounds. The compounds have antiviral activity.

  提供了以下式子的化合物：其中RN1是公式G1-NX1X2的取代基，其中G1是可选的进一步取代的烷基，它与RN2一起可选地形成环状基团，而且X1和X2分别是H或N取代基，或X1和X2一起形成杂环环，或X1与G1一起形成环状基团，而X2是H或N取代基; Z1、Z2、Z3和Z4中的每一个都是H或取代基，或Z1、Z2、Z3和Z4中的两个一起形成可选的取代环，而且至少Z1、Z2、Z3和Z4中的一个不是H，以及其盐、制药组合物和使用该化合物的方法。这些化合物具有抗病毒活性。
• PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
  申请人：Anhui New Star Pharmaceutical Development Co., Ltd

  公开号：EP3424929A1

  公开（公告）日：2019-01-09

  The present invention relates to compounds (I) capable of inhibiting the Mstl/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.

  本发明涉及能够抑制Mstl/2蛋白激酶活性的化合物（I）、其制备方法、包含该化合物的药物组合物，以及该化合物和包含该化合物的药物组合物在制备药物中的用途，以促进组织和器官的修复和再生、促进干细胞增殖和体细胞去分化、免疫抑制，以及预防或治疗与神经紊乱和局部缺血有关的疾病。
• Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor
  申请人：Heptares Therapeutics Limited

  公开号：US10961225B2

  公开（公告）日：2021-03-30

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐，其中 Q、R1、R2、R3 和 R4 如本文所定义。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR
  申请人：Heptares Therapeutics Limited

  公开号：US20200325118A1

  公开（公告）日：2020-10-15

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R 1 , R 2 , R 3 and R 4 are as defined herein.